Compare Lam Research Corporation (LRCX) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Teladoc Health Inc — how do they compare? Lam Research Corporation trades at $319.8 (market cap $383.63B), while Teladoc Health Inc trades at $9.78 (market cap $1.74B). The key difference: Lam Research Corporation is far larger — about 220.5× Teladoc Health Inc's market cap, and Lam Research Corporation pays a 0.34% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| LRCX | TDOC | |
|---|---|---|
Market Cap | $383.63B | $1.74B |
Sector | Technology | Health |
52-Week High | $433.33 | $9.72 |
52-Week Low | $94.84 | $4.47 |
Enterprise Value | $382.61B | $2.03B |
Dividend Yield | 0.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $306.96, down 2.02% amid semiconductor sector weakness. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $1.47 versus $1.36 expected, continuing a pattern of earnings outperformance. Valuation metrics remain elevated with P/E at 59.22 and P/S at 18.3, reflecting premium pricing for AI-driven growth prospects. Technical indicators show bearish momentum with price testing key support at $306.
Outlook remains positive based on analyst consensus with $393 price target (78% buy ratings), though near-term risks include semiconductor cycle volatility and rich valuations. The company's positioning in AI chip manufacturing equipment and strong cash flow generation ($6.17B operating cash flow in 2025) supports long-term growth potential despite sector headwinds.
TDOC trades at $9.63, up 2.12% today, with a bullish technical signal from moving averages and a neutral RSI near 60. Revenue remains stable around $2.5 billion, but net losses persist with a -6.81% margin. Recent news highlights expansion through the Walmart partnership and upcoming Q2 2026 earnings. The stock shows resilience despite negative profitability, supported by a low P/S ratio of 0.67 and improving cash flow trends from operations.
Outlook is mixed: cost-cutting and partnerships offer growth potential, but sustained losses and high debt pose risks. Analysts are cautious with a $8.75 price target below current levels, reflecting concerns over profitability. Investors should weigh the recovery narrative against financial challenges, with earnings on July 29, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
